Physician profile
Timothy Ryan
NPI 1790721520
$16,662.00
in general payments reported to CMS, 2019-2025
68 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,971 · 2020: $1,685 · 2021: $2,784 · 2022: $2,441 · 2023: $2,390 · 2024: $2,490 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,761 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,761.39 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,688.28 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Novo Nordisk INC | $2,346.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,575.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,181.86 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $1,017.38 | 2021-2025 | Vraylar, Dalvance, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $632.24 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $557.31 | 2019-2024 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $541.45 | 2019-2025 | Verquvo, Dificid, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $453.58 | 2022-2025 | |
| Pfizer INC. | $421.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $361.52 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $353.53 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $345.66 | 2019-2023 | |
| Grifols USA, LLC | $266.06 | 2020-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $263.87 | 2019-2024 | Uzedy, Austedo Xr |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.